| Assessing the predictive role of tumor sidedness in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials. |
Germani MM |
Cremolini C |
| J Clin Oncol 43 (no. 16_suppl): 3538 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3538 |
|
|
| The prognostic and predictive role of HER2 amplification/overexpression and HER2 mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials |
Germani MM |
Cremolini C |
| J Clin Oncol 43 (no. 16_suppl): 3537 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3537 |
|
|
| 28P Long-term survival and treatment (tx) patterns in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced NSCLC treated with first-line (1L) osimertinib (osi): German cohort of a global real-world (rw) observational study |
Frank Griesinger |
Michael Thomas |
| ESMO Open 9 (suppl. 3): 102607 |
Poster |
2024 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.esmoop.2024.102607 |
|
|
| Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212) |
Stahler A |
Modest DP |
| Clin Cancer Res 30(7): 1256-63 |
Vollpublikation |
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
PanaMa |
AIO KRK 0212 |
| doi.org/10.1158/1078-0432.CCR-23-3023 |
|
|
| Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial |
Ballhausen A |
Modest DP |
| ESMO Open 9(7): 103628 |
Abstract |
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
PanaMa |
AIO KRK 0212 |
| doi.org/10.1016/j.esmoop.2024.103628 |
|
|
| Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study |
Li M |
Härtel N |
| J Geriatr Oncol 15(7):101838 |
|
2024 |
|
Ösophagus-/Magenkarzinome
|
RAMONA |
|
| doi.org/10.1016/j.jgo.2024.101838 |
|
|
| Phase 1/2 Randomized, Open-label, Multicenter, Simon Two-stage Study of Pelareorep Combined with Modified FOLFIRINOX +/- Atezolizumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma |
Arnold D |
Heineman C |
| J Clin Oncol 42 (suppl 16):TPS4203 |
Abstract |
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1200/JCO.2024.42.16_suppl.TPS4203 |
|
|
| 100P Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany. |
Collienne M |
Loges S |
| ESMO Open 9 (suppl 6) |
Abstract |
2024 |
|
|
CONNECT |
AIO-TF-0122 |
| doi.org/10.1016/j.esmoop.2024.103840 |
|
|
| Corrigendum to “Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)”: [ESMO Open 7 (2024) 100552]. |
Hartlapp I |
Kunzmann V |
| ESMO Open 9 (5) |
Sonstige |
2024 |
|
Pankreaskarzinom
|
NEOLAP |
AIO-PAK-0113 |
|
|
|
| Corrigendum to “Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)”: [ESMO Open 7 (2024) 100552]. |
Hartlapp I |
Kunzmann V |
| ESMO Open 9 (10) |
Sonstige |
2024 |
|
Pankreaskarzinom
|
NEOLAP |
AIO-PAK-0113 |
|
|
|
